Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience
Ann Hematol
.
2024 Oct;103(10):4333-4336.
doi: 10.1007/s00277-024-05971-x.
Epub 2024 Aug 28.
Authors
Bahga Katamesh
1
2
,
Ahmad Nanaa
1
3
,
Rong He
4
,
David Viswanatha
4
,
Patricia T Greipp
4
,
Kurt Bessonen
5
,
Phuong Nguyen
4
,
Dragan Jevremovic
4
,
Cecilia Arana Yi
6
,
James Foran
7
,
Kebede Begna
1
,
Naseema Gangat
1
,
Abhishek Mangaonkar
1
,
Antoine N Saliba
1
,
Mrinal M Patnaik
1
,
William J Hogan
1
,
Mark Litzow
1
,
Ayalew Tefferi
1
,
Mithun Vinod Shah
1
,
Hassan B Alkhateeb
1
,
Aref Al-Kali
8
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA.
2
University of Connecticut School of Medicine, Farmington, CT, 06030, USA.
3
John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, 60612, USA.
4
Division of Hematopathology, Mayo Clinic, Rochester, MN, 55905, USA.
5
Division of Molecular Hematology, Mayo Clinic, Rochester, MN, 55905, USA.
6
Division of Hematology, Mayo Clinic, Scottsdale, AZ, 85259, USA.
7
Division of Hematology, Mayo Clinic, Jacksonville, FL, 32224, USA.
8
Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA. alkali.aref@mayo.edu.
PMID:
39196377
DOI:
10.1007/s00277-024-05971-x
No abstract available
Publication types
Letter